Source: PR Newswire

Press Release: Plexium : Plexium Announces Two Oral Presentations and Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

/PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation company, today announced that initial Phase 1 clinical results...

Read full article »

Plexium's Competitors | Plexium's News | Plexium's Financials

Followers on Owler

Est. Annual Revenue

$5.0-25M

Est. Employees

25-100

President & CEO

Michael Martin

CEO Approval Rating

86/100

Plexium is a California-based biotechnology company that develops a platform that provides targeted protein degradation therapies for the treatment of cancer.